Notice Number: NOT-TR-18-002
Release Date: November 7, 2017
Estimated Publication Date of Announcement: March 2018
First Estimated Application Due Date: August 2018
Earliest Estimated Award Date: June/August 2019
Earliest Estimated Start Date: June/August 2019
National Center for Advancing Translational Sciences (NCATS)
The purpose of this Notice is to indicate the intent to re-issue Funding Opportunity Announcement (FOA) Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54) (RFA-TR-13-002) and to alert potential applicants of the objectives of this cooperative research program. The FOA will be open to current Rare Diseases Clinical Research Consortia (RDCRC) awardees as well as to new applicants.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in Spring 2018 with the expected application due date in Fall 2018.
The Rare Diseases Clinical Research Consortia (RDCRC) FOA will utilize the U54 activity code. Additional information about the planned FOA is provided below.
The purpose of the Rare Diseases Clinical Research Network Program is to facilitate clinical research in rare diseases through support for: 1) collaborative clinical research in rare diseases, including observational studies and clinical trials; 2) pilot/demonstration clinical research projects; (3) training of clinical investigators in rare diseases research; 4) clinical data management that incorporates novel approaches and technologies for data management, data collection, data mining, and data sharing across rare diseases, data types, and platforms; and 5) access to information related to rare diseases for basic and clinical researchers, academic and practicing physicians, patients, and the lay public.
Each RDCRC must include a consortium of clinical investigators, institutions, and relevant organizations, including active engagement of patient organizations, for the study of a group of a minimum of three rare diseases, or a therapeutic area or concept (e.g., genetic mutation, organ or organelle).
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Please direct all inquiries to:
Please direct all inquiries via email to:
Anne Pariser, M.D.
National Center for Advancing Translational Sciences